Dose Escalation of Allogeneic Adipose Derived Stroma/Stem Cells for the Treatment of Crohn's Fistula

Inclusion Criteria:

• Patients over 18 years old,

• Patients who signed the informed consent,

• Patient affiliated to a social security system,

• Controlled luminal Crohn's disease characterized by an Harvey-Bradshaw score less orequal than 8 and diagnosed on clinical, endoscopic, histological and/or radiologicalcriteria for more than 3 months,

• Colonoscopy less than a year old without ulcer in the rectum,

• Presence of complex chronic perianal fistula with a maximum of two internal portsand three external ports,

• Patient treated with a combined treatment (drainage on setons + anti-TNFα) and whofailed conventional treatment after 6 months and whose intraluminal disease (intestinal damage) is controlled

Exclusion Criteria:

• Refusal of the patient to participate in the study,

• Positive QuantiFERON test,

• Patient with transplanted organ,

• History of cancer in the last five years or lympho-proliferative disease,

• Persistent bacterial or viral infection,

• Patient with a contraindication to MRI,

• Known allergy to Gadolinium,

• Known allergy to Albumine,

• End-stage organ failure,

• Pregnant or breastfeeding women,

• Women of childbearing age without effective contraception throughout the duration ofthe study,

• Patient under judicial protection, under guardianship or curatorship.

• Patient previously treated with ALOFISEL®